Use of inhibitors of bruton's tyrosine kinase (BTK)
View Patent ↗Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
1. A method for treating marginal zone lymphoma (MZL) in an individual in need thereof, wherein the individual has received at least one prior anti-CD20-based therapy, comprising:
administering to the individual once per day about 560 mg of an oral dose of a compound having the structure:
2. The method of claim 1 , wherein the MZL is relapsed or refractory MZL.
3. The method of claim 1 , wherein the MZL is extranodal marginal zone B cell lymphoma.
4. The method of claim 1 , wherein the MZL is extranodal marginal zone B-cell lymphoma-mucosa-associated lymphoid tissue (MALT) lymphoma.
5. The method of claim 1 , wherein the MZL is nodal marginal zone B-cell lymphoma.
6. The method of claim 1 , wherein the MZL is splenic marginal zone B-cell lymphoma.
7. The method of claim 1 , wherein the compound is in the form of a solid oral dosage form.
8. The method of claim 1 , wherein, following administration of the compound, the individual achieves a stable disease, a partial response, or a complete response.
9. The method of claim 1 , wherein, following administration of the compound, the individual achieves a partial response or a complete response.
10. The method of claim 1 , wherein, following administration of the compound, the individual achieves a complete response.
11. The method of claim 1 , wherein, following administration of the compound, the individual does not experience a progressive disease.